Share This Page
Drugs in ATC Class A07DA
✉ Email this page to a colleague
Drugs in ATC Class: A07DA - Antipropulsives
ATC Class A07DA Antipropulsives: market dynamics and patent landscape
ATC Class A07DA (“antipropulsives,” antidiarrheal anticholinergics and related agents) is dominated by low-cost, long-tenured branded and generic small molecules with limited recent entrant volume. Patent activity is concentrated in (1) prodrug/derivative chemistry, (2) formulation and device-linked delivery (especially controlled release and locally acting gastroenteric delivery), and (3) method-of-use claims that tie use to narrower etiologies (infectious diarrhea, IBS-diarrhea subsets) or specific dosing regimens. Competitive pressure is typically driven by generic erosion rather than new molecular breakthroughs.
Patent estates are fragmented across jurisdictions, with meaningful exclusivity usually ending before the next major commercial cycle. Where reformulations exist (extended release capsules/tablets, combinations with antispasmodics or adsorbents), the practical value of the estate is the ability to sustain a branded NDC through formulation-based Orange Book listings and follow-on patents, not the ability to block all generics.
Which drugs are included in ATC A07DA antipropulsives and why does it matter for patents?
Featured-snippet answer: A07DA antipropulsives is a class bucket in ATC. Patent outcomes depend on the specific active ingredient(s) that sit inside the bucket, because each has its own FDA NDA/ANDA listing status, patent thicket, and exclusivity expiries.
What active ingredients typically drive A07DA market dynamics
Common commercial antipropulsives used for diarrhea symptom control often include:
- Loperamide (OTC and Rx in many markets; antidiarrheal that slows GI motility)
- Diphenoxylate/atropine (Rx in some markets)
- Other antidiarrheal motility modifiers depending on country-specific ATC mapping
Patent strategies differ by active ingredient:
- Loperamide tends to have fewer “blocking” new chemical entity patents today, so estates shift to controlled-release and specific combinations.
- Diphenoxylate/atropine behaves similarly, with older foundational patents long expired in most markets and remaining value in formulations and indications.
What patents protect antipropulsives in ATC A07DA (loperamide and diphenoxylate/atropine)?
A7DA protection patterns generally split into three buckets: composition-of-matter, formulation/controlled-release, and method-of-use.
Composition-of-matter: prodrugs, salts, and derivatives
Where still active, these claims usually target:
- specific salts or crystalline forms
- derivatives or prodrug forms with improved release or reduced GI side effects
- stereochemical or polymorphic variants that support “new patentable subject matter”
Formulation patents: the primary tail after primary MOA patents expire
In antipropulsives, formulation patents often dominate litigation and generic design-around:
- extended release matrices (polymer-based)
- gastro-resistant coatings
- microencapsulation for delayed release in the GI tract
- fixed-dose combinations (if permitted by the NDA labeling)
Method-of-use patents: narrower labeling and dosing regimen claims
Method-of-use protection is typically used to:
- define dosing for specific patient subgroups
- tie use to etiology-defined diarrhea or limited treatment durations
- claim therapeutic regimens that can be carved into branded labeling
How strong is the patent estate for A07DA antipropulsives?
Featured-snippet answer: The estate is usually “narrow but long” if centered on formulation and line extensions, and “thin” if centered on early composition-of-matter that has already expired.
Estate strength drivers
Key factors that determine enforceability and blocking power:
- Whether patents are listed in FDA Orange Book against an approved NDA/ANDA product
- Whether claims cover features a generic must include to match the branded product’s bioequivalence profile
- Whether there is historical Paragraph IV litigation that confirms whether the patents are considered commercially meaningful
- Jurisdictional breadth: US-only estates versus multinational coverage
Typical outcome
For most A07DA products, generic entry risk is moderate to high unless:
- formulation patents remain unexpired and listed,
- method-of-use claims are tied to labeling the FDA will accept, and
- settlement agreements lock in a launch schedule.
When do A07DA antipropulsives lose exclusivity in the US?
Featured-snippet answer: Exclusivity timing is usually governed by the expiration of the last FDA-listed Orange Book patent (often formulation) plus any periods of non-patent exclusivity tied to the NDA (where applicable). For legacy antidiarrheals, primary exclusivity is typically far behind the market.
What actually controls generic launch timing
For A07DA, the practical US timeline is:
- Orange Book patent expiry (first and last listed)
- Any pediatric exclusivity extensions (if triggered)
- Regulatory exclusivity (if applicable; less relevant for old actives)
- Settlement agreements following Paragraph IV filings (if present)
What is the Orange Book status of loperamide and other A07DA antipropulsives?
Featured-snippet answer: Orange Book status is product- and manufacturer-specific. The most actionable filings for market entry are those with remaining listed patents tied to extended release, specific strengths, or combinations.
How Orange Book listings affect competitive risk
- If only older foundational patents remain, generic entry is less constrained.
- If listed formulation patents remain, generics may face:
- delayed approval (if granted 30-month stay via Paragraph IV)
- injunction risk
- required design-arounds that change release profile, sometimes triggering different formulation development costs.
What Paragraph IV challenges exist for A07DA antipropulsives and what happened in litigation?
Featured-snippet answer: Paragraph IV activity in A07DA tends to be sporadic and centered on product-specific reformulations rather than core actives, because the core actives have long-expired protection.
How to evaluate whether a Paragraph IV affects commercial reality
When assessing Paragraph IV risk for A07DA:
- Identify which patents are asserted (formulation vs method-of-use)
- Check whether the challenger settled and under what launch date
- Track whether the NDA product is extended release, multi-layer, or otherwise formulation-sensitive
Litigation-driven settlement structures
Common settlement outcomes in this category include:
- delayed generic launch date until patent expiry
- partial carve-outs by strength, dosage form, or indication
- cross-licenses only if needed to resolve overlapping formulation features
Which formulations of antipropulsives are typically protected by patents (IR vs ER, gastro-resistant, combinations)?
Featured-snippet answer: Patents most often protect extended-release and gastro-resistant formulations, plus fixed-dose combinations, because these create measurable differentiation that generics must replicate.
Formulation clusters that attract protection
- Extended-release matrices
- sustained motility suppression
- Delayed or gastro-resistant coatings
- reduce variability in GI transit
- Layered release systems
- mimic branded pharmacokinetic curves
- Combination dosage forms
- fixed combinations may implicate additional IP beyond the base active
Design-around feasibility
Generic feasibility depends on:
- whether the branded release mechanism is described with specificity in claims,
- whether performance requirements (dissolution profile) are hard-coded into the patent claim scope, and
- whether the generic can choose alternative excipients without infringing.
How do A07DA antipropulsives compare with other antidiarrheal classes on patent strategy and market dynamics?
Featured-snippet answer: A07DA’s IP strategy is usually formulation- and label-driven, while other antidiarrheal classes (adsorbents, antisecretory agents, gut microbiome approaches) tend to have different IP lifecycles and development timing.
Comparison points
- A07DA (antipropulsives): symptom control of reduced motility; older actives, fewer new MOAs; reformulation is the main “tail.”
- A07BA (adsorbents/antimicrobials): may see different active pipelines and more frequent regulatory changes.
- A07EC (racecadotril etc., antisecretory): different MOA and patent trajectory due to distinct NDAs and clinical packages.
Which companies hold key IP positions in A07DA antipropulsives?
Featured-snippet answer: In A07DA, branded holders and formulation licensors typically protect line extensions, while generic manufacturers focus on entry via Abbreviated New Drug Applications and design-around formulations.
Competitive landscape pattern
- Branded IP holders: defend formulation differences and any active ingredient variants that remain within patent scope.
- Generic challengers: prioritize Paragraph IV filings when listed formulation patents remain, and avoid litigation where the generic can match via non-infringing formulation choices.
What generic entry risks exist for A07DA antipropulsives by dosage form?
Featured-snippet answer: The highest risk is for extended-release and gastro-resistant branded products with active Orange Book listings; the lowest risk is for immediate-release legacy tablets/capsules where patents are largely expired.
Entry risk matrix (directional)
- Immediate-release (IR): high probability of generic availability; lower litigation frequency
- Extended-release (ER): higher risk when the ER mechanism is claim-covered and listed
- Combination products: risk increases due to multi-IP overlap (active + formulation + combination ratio)
How do settlement agreements shape timing for A07DA antipropulsives?
Featured-snippet answer: Settlements often become the true exclusivity clock in A07DA reformulations, overriding theoretical patent expiry and controlling launch dates by strength and dosage form.
Settlement effects on market structure
- Temporary duopoly: branded + generic delayed until agreed trigger date
- Strength carve-outs: branded retains selected NDCs while generics launch others
- Label timing: branded may preserve the protected label longer, narrowing generic substitution
What regulatory pathway constraints affect A07DA antipropulsives (505(b)(2) vs ANDA)?
Featured-snippet answer: Generic entry is usually ANDA-driven for A07DA, but reformulated branded products sometimes use 505(b)(2) to support new formulations or labeling, creating new listed patents.
Pathway implications
- ANDA: requires bioequivalence; may still face patent litigation if formulation patents exist.
- 505(b)(2): can create new data packages that support formulation-specific labeling and new patent listings.
Key market dynamics: pricing, substitution, and OTC-to-Rx transitions
Featured-snippet answer: In A07DA, market outcomes hinge on generic substitution speed, OTC access, and how much branded differentiation is preserved by formulation and labeling.
Commercial drivers
- OTC availability: compresses pricing power and reduces the value of long legal delays
- Substitution rules: increase generic capture once products are approved
- Reformulation cycles: can extend brand presence through ER or combination SKUs
- Safety labeling: may shift prescribing practices and drive demand away from certain dosing regimes
Key Takeaways
- A07DA antipropulsives are dominated by legacy small molecules, so the patent landscape is typically concentrated in formulation line extensions rather than new chemical entity protections.
- Patent “blocking power” usually depends on whether formulation patents remain listed in the Orange Book and whether they cover ER/gastro-resistant features that generics must replicate.
- Generic entry risk is highest for patented extended-release or combination products; it is generally lower for immediate-release legacy forms with expired primary patents.
- In practice, Paragraph IV filings and settlement agreements, not just theoretical patent expiry dates, set the market entry timeline.
FAQs
1. What patents are most likely to be asserted for A07DA antipropulsives in US Hatch-Waxman cases?
Formulation and dosing regimen claims tied to Orange Book-listed products, especially extended-release and gastro-resistant systems.
2. Do A07DA antipropulsives face biosimilar risk?
No. A07DA comprises small-molecule antidiarrheal motility modifiers, not biologics.
3. How do pediatric exclusivity and patent term adjustments change A07DA timelines?
They can extend the last listed patent expiry by discrete periods, but the effect is product-specific and most relevant when formulation patents are still active.
4. Can generics avoid infringement on ER antipropulsives by changing excipients?
Sometimes. Design-around feasibility depends on claim scope and whether dissolution/release characteristics are claim-limited.
5. Why do some A07DA brands persist long after core patents expire?
Line extensions through formulation changes, new strengths, combinations, and label-supported indications that keep Orange Book listings alive.
References
No sources were provided in the prompt, and no cited sources can be generated without verifiable FDA/Orange Book, patent registry, or litigation records.
More… ↓
